Roffman Miller Associates Inc. PA Acquires 945 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Roffman Miller Associates Inc. PA boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,493 shares of the medical research company’s stock after buying an additional 945 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Thermo Fisher Scientific were worth $17,778,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Sugarloaf Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock valued at $156,000 after purchasing an additional 19 shares during the last quarter. Rosenberg Matthew Hamilton raised its holdings in Thermo Fisher Scientific by 3.7% during the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after buying an additional 19 shares during the period. Tsfg LLC boosted its stake in Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after buying an additional 19 shares during the period. Pacifica Partners Inc. raised its stake in shares of Thermo Fisher Scientific by 16.5% in the fourth quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 20 shares during the period. Finally, Retirement Planning Group LLC boosted its stake in shares of Thermo Fisher Scientific by 4.9% during the 4th quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company’s stock worth $237,000 after purchasing an additional 21 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TMO. Citigroup began coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Royal Bank of Canada increased their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Evercore ISI lifted their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Finally, Barclays lifted their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $606.76.

Thermo Fisher Scientific Price Performance

TMO stock traded up $2.99 during midday trading on Friday, reaching $574.72. The stock had a trading volume of 704,185 shares, compared to its average volume of 1,552,624. The company’s fifty day simple moving average is $573.08 and its 200 day simple moving average is $529.36. The company has a market cap of $219.38 billion, a price-to-earnings ratio of 36.70, a price-to-earnings-growth ratio of 2.44 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.